Evidenced-based guidelines for management of infants and children with community-acquired pneumonia (CAP) were prepared by an expert panel comprising clinicians and investigators representing community pediatrics, public health, and the pediatric specialties of critical care, emergency medicine, hospital medicine, infectious diseases, pulmonology, and surgery. These guidelines are intended for use by primary care and subspecialty providers responsible for the management of otherwise healthy infants and children with CAP in both outpatient and inpatient settings. Site-of-care management, diagnosis, antimicrobial and adjunctive surgical therapy, and prevention are discussed. Areas that warrant future investigations are also highlighted.
Evidenced-based guidelines for management of infants and children with community-acquired pneumonia (CAP) were prepared by an expert panel comprising clinicians and investigators representing community pediatrics, public health, and the pediatric specialties of critical care, emergency medicine, hospital medicine, infectious diseases, pulmonology, and surgery. These guidelines are intended for use by primary care and subspecialty providers responsible for the management of otherwise healthy infants and children with CAP in both outpatient and inpatient settings. Site-of-care management, diagnosis, antimicrobial and adjunctive surgical therapy, and prevention are discussed. Areas that warrant future investigations are also highlighted.
EXECUTIVE SUMMARY
Guidelines for the management of community-acquired pneumonia (CAP) in adults have been demonstrated to decrease morbidity and mortality rates [1, 2] . These guidelines were created to assist the clinician in the care of a child with CAP. They do not represent the only approach to diagnosis and therapy; there is considerable variation among children in the clinical course of pediatric CAP, even with infection caused by the same pathogen. The goal of these guidelines is to decrease morbidity and mortality rates for CAP in children by presenting recommendations for clinical management that can be applied in individual cases if deemed appropriate by the treating clinician.
This document is designed to provide guidance in the care of otherwise healthy infants and children and addresses practical questions of diagnosis and management of CAP evaluated in outpatient (offices, urgent care clinics, emergency departments) or inpatient settings in the United States. Management of neonates and young infants through the first 3 months, immunocompromised children, children receiving home mechanical ventilation, and children with chronic conditions or underlying lung disease, such as cystic fibrosis, are beyond the scope of these guidelines and are not discussed.
Summarized below are the recommendations made in the new 2011 pediatric CAP guidelines. The panel followed a process used in the development of other Infectious Diseases Society of America (IDSA) guidelines, which included a systematic weighting of the quality of the evidence and the grade of the recommendation [3] (Table 1) . A detailed description of the methods, background, and evidence summaries that support each of the recommendations can be found in the full text of the guidelines.
SITE-OF-CARE MANAGEMENT DECISIONS
I. When Does a Child or Infant With CAP Require Hospitalization? Recommendations 1. Children and infants who have moderate to severe CAP, as defined by several factors, including respiratory distress and hypoxemia (sustained saturation of peripheral oxygen [SpO 2 ], ,90 % at sea level) (Table 3) should be hospitalized for management, including skilled pediatric nursing care. (strong recommendation; high-quality evidence)
2. Infants less than 3-6 months of age with suspected bacterial CAP are likely to benefit from hospitalization. (strong recommendation; low-quality evidence)
3. Children and infants with suspected or documented CAP caused by a pathogen with increased virulence, such as community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) should be hospitalized. (strong recommendation; lowquality evidence) 4. Children and infants for whom there is concern about careful observation at home or who are unable to comply with therapy or unable to be followed up should be hospitalized.
(strong recommendation; low-quality evidence) 15. In improving patients who otherwise meet criteria for discharge, a positive blood culture with identification or 28. Acute-phase reactants need not be routinely measured in fully immunized children with CAP who are managed as outpatients, although for more serious disease, acute-phase reactants may provide useful information for clinical management. (strong recommendation; low-quality evidence)
29. In patients with more serious disease, such as those requiring hospitalization or those with pneumonia-associated complications, acute-phase reactants may be used in conjunction with clinical findings to assess response to therapy. (weak recommendation; low-quality evidence) Pulse Oximetry 30. Pulse oximetry should be performed in all children with pneumonia and suspected hypoxemia. The presence of hypoxemia should guide decisions regarding site of care and further diagnostic testing. (strong recommendation; moderatequality evidence)
Chest Radiography Initial Chest Radiographs: Outpatient 31. Routine chest radiographs are not necessary for the confirmation of suspected CAP in patients well enough to be treated in the outpatient setting (after evaluation in the office, clinic, or emergency department setting). (strong recommendation; high-quality evidence) 32. Chest radiographs, posteroanterior and lateral, should be obtained in patients with suspected or documented hypoxemia or significant respiratory distress (Table 3 ) and in those with failed initial antibiotic therapy to verify the presence or absence of complications of pneumonia, including parapneumonic effusions, necrotizing pneumonia, and pneumothorax. 36. Routine daily chest radiography is not recommended in children with pneumonia complicated by parapneumonic effusion after chest tube placement or after videoassisted thoracoscopic surgery (VATS), if they remain clinically stable. (strong recommendation; low-quality evidence)
37. Follow-up chest radiographs should be obtained in patients with complicated pneumonia with worsening respiratory distress or clinical instability, or in those with persistent fever that is not responding to therapy over 48-72 hours. (strong recommendation; low-quality evidence) 38. Repeated chest radiographs 4-6 weeks after the diagnosis of CAP should be obtained in patients with recurrent pneumonia involving the same lobe and in patients with lobar collapse at initial chest radiography with suspicion of an anatomic anomaly, chest mass, or foreign body aspiration. (strong recommendation; moderatequality evidence) 42. Amoxicillin should be used as first-line therapy for previously healthy, appropriately immunized infants and preschool children with mild to moderate CAP suspected to be of bacterial origin. Amoxicillin provides appropriate coverage for Streptococcus pneumoniae, the most prominent invasive bacterial pathogen. Table 5 lists preferred agents and alternative agents for children allergic to amoxicillin (strong recommendation; moderate-quality evidence)
43. Amoxicillin should be used as first-line therapy for previously healthy appropriately immunized school-aged children and adolescents with mild to moderate CAP for S. pneumoniae, the most prominent invasive bacterial pathogen. Atypical bacterial pathogens (eg, M. pneumoniae), and less common lower respiratory tract bacterial pathogens, as discussed in the Evidence Summary, should also be considered in management decisions. (strong recommendation; moderatequality evidence) 44. Macrolide antibiotics should be prescribed for treatment of children (primarily school-aged children and adolescents) evaluated in an outpatient setting with findings compatible with CAP caused by atypical pathogens. Laboratory testing for M. pneumoniae should be performed if available in a clinically relevant time frame. 45. Influenza antiviral therapy (Table 6) should be administered as soon as possible to children with moderate to severe CAP consistent with influenza virus infection during widespread local circulation of influenza viruses, particularly for those with clinically worsening disease documented at the time of an outpatient visit. Because early antiviral treatment has been shown to provide maximal benefit, treatment should not be delayed until confirmation of positive influenza test results. Negative results of influenza diagnostic tests do not conclusively exclude influenza disease. Treatment after 48 hours of symptomatic infection may still provide clinical benefit to those with more severe disease. (strong recommendation; moderatequality evidence) Inpatients 46. Ampicillin or penicillin G should be administered to the fully immunized infant or school-aged child admitted to a hospital ward with CAP when local epidemiologic data document lack of substantial high-level penicillin resistance for invasive S. pneumoniae. Other antimicrobial agents for empiric therapy are provided in Table 7 . (strong recommendation; moderate-quality evidence)
47. Empiric therapy with a third-generation parenteral cephalosporin (ceftriaxone or cefotaxime) should be prescribed for hospitalized infants and children who are not fully immunized, in regions where local epidemiology of invasive pneumococcal strains documents high-level penicillin resistance, or for infants and children with life-threatening infection, including those with empyema (Table 7) . Nonb-lactam agents, such as vancomycin, have not been shown to be more effective than third-generation cephalosporins in the treatment of pneumococcal pneumonia for the degree of resistance noted currently in North America. (weak recommendation; moderate-quality evidence)
48. Empiric combination therapy with a macrolide (oral or parenteral), in addition to a b-lactam antibiotic, should be prescribed for the hospitalized child for whom M. pneumoniae and C. pneumoniae are significant considerations; diagnostic testing should be performed if available in a clinically relevant time frame (Table 7) . (weak recommendation; moderate-quality evidence)
49. Vancomycin or clindamycin (based on local susceptibility data) should be provided in addition to b-lactam therapy if Recommendations 50. Antibiotic exposure selects for antibiotic resistance; therefore, limiting exposure to any antibiotic, whenever possible, is preferred. (strong recommendation; moderate-quality evidence) 51. Limiting the spectrum of activity of antimicrobials to that specifically required to treat the identified pathogen is preferred. (strong recommendation; low-quality evidence)
52. Using the proper dosage of antimicrobial to be able to achieve a minimal effective concentration at the site of infection is important to decrease the development of resistance. (strong recommendation; low-quality evidence) 53. Treatment for the shortest effective duration will minimize exposure of both pathogens and normal microbiota to antimicrobials and minimize the selection for resistance. (strong recommendation; low-quality evidence) Recommendation 57. History and physical examination may be suggestive of parapneumonic effusion in children suspected of having CAP, but chest radiography should be used to confirm the presence of pleural fluid. If the chest radiograph is not conclusive, then NOTE. Check Centers for Disease Control and Prevention Website (http://www.flu.gov/) for current susceptibility data. a In children for whom prophylaxis is indicated, antiviral drugs should be continued for the duration of known influenza activity in the community because of the potential for repeated and unknown exposures or until immunity can be achieved after immunization.
b Amantadine and rimantadine should be used for treatment and prophylaxis only in winter seasons during which a majority of influenza A virus strains isolated are adamantine susceptible; the adamantanes should not be used for primary therapy because of the rapid emergence of resistance. However, for patients requiring adamantane therapy, a treatment course of 7 days is suggested, or until 24-48 hours after the disappearance of signs and symptoms.
further imaging with chest ultrasound or computed tomography (CT) is recommended. (strong recommendation; high-quality evidence)
X. What Factors Are Important in Determining Whether Drainage of the Parapneumonic Effusion Is Required?
Recommendations 58. The size of the effusion is an important factor that determines management (Table 8, Figure 1 ). (strong recommendation; moderate-quality evidence) 59. The child's degree of respiratory compromise is an important factor that determines management of parapneumonic effusions (Table 8, Figure 1 ) (strong recommendation; moderatequality evidence) Oral azithromycin (10 mg/kg on day 1, followed by 5 mg/kg/day once daily on days 2-5 to a maximum of 500 mg on day 1, followed by 250 mg on days 2-5); alternatives: oral clarithromycin (15 mg/kg/day in 2 doses to a maximum of 1 g/day); erythromycin, doxycycline for children .7 years old a. Clinical and laboratory assessment of the current severity of illness and anticipated progression in order to determine whether higher levels of care or support are required. (strong recommendation; low-quality evidence) b. Imaging evaluation to assess the extent and progression of the pneumonic or parapneumonic process. (weak recommendation; low-quality evidence) c. Further investigation to identify whether the original pathogen persists, the original pathogen has developed resistance to the agent used, or there is a new secondary infecting agent. (weak recommendation; low-quality evidence)
73. A BAL specimen should be obtained for Gram stain and culture for the mechanically ventilated child. (strong recommendation; moderate-quality evidence) 74. A percutaneous lung aspirate should be obtained for Gram stain and culture in the persistently and seriously ill child for whom previous investigations have not yielded a microbiologic diagnosis. (weak recommendation; low-quality evidence) Figure 1 . Management of pneumonia with parapneumonic effusion; abx, antibiotics; CT, computed tomography; dx, diagnosis; IV, intravenous; US, ultrasound; VATS, video-assisted thoracoscopic surgery.
75. An open lung biopsy for Gram stain and culture should be obtained in the persistently and critically ill, mechanically ventilated child in whom previous investigations have not yielded a microbiologic diagnosis. (weak recommendation; low-quality evidence) 80. Patients are not eligible for discharge if they have substantially increased work of breathing or sustained tachypnea or tachycardia (strong recommendation; high-quality evidence)
81. Patients should have documentation that they can tolerate their home anti-infective regimen, whether oral or intravenous, and home oxygen regimen, if applicable, before hospital discharge. (strong recommendation; low-quality evidence) 82. For infants or young children requiring outpatient oral antibiotic therapy, clinicians should demonstrate that parents are able to administer and children are able to comply adequately with taking those antibiotics before discharge. (weak recommendation; very low-quality evidence)
83. For children who have had a chest tube and meet the requirements listed above, hospital discharge is appropriate after the chest tube has been removed for 12-24 hours, either if there is no clinical evidence of deterioration since removal or if a chest radiograph, obtained for clinical concerns, shows no significant reaccumulation of a parapneumonic effusion or pneumothorax. (strong recommendation; very low-quality evidence)
84. In infants and children with barriers to care, including concern about careful observation at home, inability to comply with therapy, or lack of availability for follow-up, these issues should be identified and addressed before discharge. (weak recommendation; very low-quality evidence)
XIX. When Is Parenteral Outpatient Therapy Indicated, In Contrast to Oral Step-Down Therapy?
Recommendations 85. Outpatient parenteral antibiotic therapy should be offered to families of children no longer requiring skilled nursing care in an acute care facility but with a demonstrated need for ongoing parenteral therapy. (weak recommendation; moderate-quality evidence)
86. Outpatient parenteral antibiotic therapy should be offered through a skilled pediatric home nursing program or through daily intramuscular injections at an appropriate pediatric outpatient facility. (weak recommendation; low-quality evidence)
87. Conversion to oral outpatient step-down therapy when possible, is preferred to parenteral outpatient therapy. 89. All infants $6 months of age and all children and adolescents should be immunized annually with vaccines for influenza virus to prevent CAP. (strong recommendation; highquality evidence)
90. Parents and caretakers of infants ,6 months of age, including pregnant adolescents, should be immunized with vaccines for influenza virus and pertussis to protect the infants from exposure. (strong recommendation; weak-quality evidence)
91. Pneumococcal CAP after influenza virus infection is decreased by immunization against influenza virus. (strong recommendation; weak-quality evidence)
92. High-risk infants should be provided immune prophylaxis with respiratory syncytial virus (RSV)-specific monoclonal antibody to decrease the risk of severe pneumonia and hospitalization caused by RSV. (strong recommendation; high-quality evidence)
